# Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

> **NCT04024137** · PHASE2 · COMPLETED · sponsor: **Guangdong Raynovent Biotech Co., Ltd** · enrollment: 172 (actual)

## Conditions studied

- Influenza A

## Interventions

- **DRUG:** ZSP1273 200 mg
- **DRUG:** Placebo
- **DRUG:** ZSP1273-400 mg
- **DRUG:** Placebo
- **DRUG:** ZSP1273-600 mg
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04024137
- **Lead sponsor:** Guangdong Raynovent Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-07
- **Primary completion:** 2020-05-18
- **Final completion:** 2020-05-18
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2020-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04024137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04024137, "Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04024137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*